Connect with us

Technology

Fresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapy

Published

on

Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settingsAvailable within NxStage® System One™ with NxView™ 4.0, Fresenius Medical Care’s FDA 510(k)-cleared software platform for kidney replacement therapy in the United StatesAggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability

BAD HOMBURG, Germany, July 20, 2026 /PRNewswire/ — Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today announced the introduction of TherapyWise™, a cloud-based analytics capability available within NxView™ 4.0, the Company’s FDA 510(k)-cleared software platform for use with the NxStage® System One™ in the United States. TherapyWise is designed to provide retrospective, program-level insight into kidney replacement therapy (KRT) delivered in acute and hospital critical care settings.

Kidney replacement therapy in the Intensive Care Unit (ICU) generates large volumes of clinical and operational data, yet trends related to therapy delivery, workflow interruptions, and alarm frequency can be difficult to assess without standardized metrics and aggregated views. TherapyWise consolidates existing data generated at the point of care and presents longitudinal summaries intended to support oversight of KRT programs across ICU units and time periods.

“Digital solutions play an increasingly important role in how critical care teams understand and manage complex therapies,” said Joe Turk, Chief Executive Officer of Care Enablement at Fresenius Medical Care. “TherapyWise reflects our continued focus on innovation in critical care by applying data analytics. This helps hospital and clinical leaders gain visibility into how kidney replacement therapy is delivered across their organizations, supporting informed discussions around workflow, consistency, and quality improvement.”

TherapyWise works by securely transmitting data from the NxStage System One with NxView to a cloud‑based platform, where information is aggregated and displayed across predefined performance indicators. These include program‑level metrics including average delivered dose compared with set dose, average treatment time per cartridge, and alarm frequency trends. The software is intended to support retrospective review and program oversight and is not designed for real‑time, patient‑specific clinical decision‑making, which remains the responsibility of attending clinicians.

TherapyWise is part of Fresenius Medical Care’s NxView 4.0 software platform and broader critical care portfolio, which combines digital infrastructure, clinical expertise, and secure data management to support hospital teams responsible for kidney replacement therapy programs.

To learn more about TherapyWise, please visit https://freseniusmedicalcare.com/en-us/products/critical-care/therapywise/.

About Fresenius Medical Care:
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,539 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company’s website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com 

Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com 

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2525
dominik.heger@freseniusmedicalcare.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-introduces-therapywise-analytics-for-kidney-replacement-therapy-302829320.html

SOURCE Fresenius Medical Care Holdings, Inc.

Continue Reading

Technology

BIDU Stockholders Have Rights – If You Lost Money Investing in Baidu, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Published

on

By

SAN DIEGO, Oct. 1, 2026 /PRNewswire/ — Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Baidu, Inc. (NASDAQ: BIDU) securities, including call options, between November 18, 2025 and August 17, 2026, inclusive (the “Class Period”). Baidu is a Chinese technology company that operates the most popular internet search engine in China.

The complaint alleges that Baidu, Inc. overstated the ability of its AI business to mitigate rapid declines in its legacy online marketing business.

Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP before the November 13, 2026, lead plaintiff deadline.

Listen to our podcast.

Why Was Baidu Sued?

According to the complaint, online Marketing Services is Baidu’s core legacy business, which represented approximately 53.1% of total revenues for the third quarter of 2025. However, Online Marketing Services revenue for the third quarter of 2025 fell 17.6% compared to the third quarter of 2024. Despite this, Baidu assured investors that its new Core AI-powered Business growth had, and would continue to, meaningfully mitigate Baidu’s Online Marketing Services decline.

The complaint alleges that, during the Class Period, defendants failed to disclose to investors:

(1) that the Company had overstated the ability of its AI business to mitigate rapid declines in its legacy online marketing business;

(2) that, as a result, the Company’s revenue was reasonably likely to decline; and

(3) that, as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Why Did BIDU Stock Drop?

The complaint alleges that on February 26, 2026, Baidu reported fourth quarter and full year 2025 financial results, revealing that total revenue fell more than 4% year over year for the fourth quarter to RMB32.74 billion (or $4.68 billion) and fell more than 3% year over year for the full year to RMB129.079 billion (or $18.458 billion). However, Baidu management assured investors its “AI-Powered Business” grew 48% year over year to RMB40 billion for fiscal year 2025, mitigating this transition. On this news, the price of Baidu American Depositary Shares (“ADS”) fell $7.50 per share or 5.65%, to close at $125.15 per share on February 26, 2026.

Then, on August 18, 2026, Baidu reported second quarter 2026 financial results, revealing that Baidu General Business revenue fell 4% year over year to RMB25.2 billion (or $3.71 billion), with Legacy Business revenue falling 23% year over year to RMB10.4 billion and total Online Marketing Services revenue falling 19% year over year to RMB13.1 billion. Critically, the Baidu Core AI-powered business fell 8% quarter over quarter to RMB12.5 billion (or $1.86 billion), its year-over-year growth having decelerated from 49% in the first quarter of 2026 to 25%, and its largest component, AI Cloud Infra, having fallen 17% quarter over quarter from RMB8.8 billion to RMB7.3 billion. On this news, the price of Baidu ADS fell $13.25 per share, or 12.73%, to close at $90.87 on August 18, 2026.

Who May Be Eligible to Participate in the Baidu Class Action?

The lawsuit seeks to represent investors who purchased or otherwise acquired Baidu, Inc. securities between November 18, 2025 and August 17, 2026. Investors who suffered losses during that period may have legal rights under the federal securities laws.

What Is a Lead Plaintiff?

The lead plaintiff is a court-appointed investor who represents the interests of all class members throughout the litigation. Stockholders who wish to lead the class action should contact Robbins LLP for information before the November 13, 2026, lead plaintiff deadline.

Serving as lead plaintiff is not required to share in any potential recovery. Investors who do not seek appointment may remain absent class members if the case proceeds and later resolves successfully.

Does It Cost Anything to Participate?

No. Robbins LLP represents investors on a contingency fee basis.

Why Robbins LLP?

A recognized leader in shareholder rights litigation, Robbins LLP represents investors in securities fraud and shareholder derivative litigation. We have helped restore more than $2 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history. 

“Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently,” said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Baidu, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Contact Robbins LLP

Investors seeking additional information about the Baidu, Inc. securities class action may contact Robbins LLP by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling (800) 350-6003.

Attorney Advertising.Past results do not guarantee a similar outcome.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bidu-stockholders-have-rights–if-you-lost-money-investing-in-baidu-inc-contact-robbins-llp-for-information-about-recovering-your-losses-302896498.html

SOURCE Robbins LLP

Continue Reading

Technology

GMP Labeling Celebrates 40 Years of US Manufacturing for Regulated Industries

Published

on

By

GRANITE BAY, Calif., Oct. 1, 2026 /PRNewswire/ — As pharmaceutical and biotechnology sectors navigate evolving global supply chain risks, GMP Labeling Inc. is utilizing Manufacturing Day 2026 to highlight its nearly 40-year history as a domestic manufacturer of critical compliance identification. The company specializes in the foundational traceability components required for stringent regulatory environments. View the company’s core capabilities and full catalog.

While often viewed as minor components, labels for quality control, sample identification, and equipment status represent a potential vulnerability in highly regulated production lines. Material inconsistencies or shipping delays can interrupt manufacturing workflows, complicate federal audits, and compromise the integrity of quality records.

“In the highly regulated environments of biotechnology and medical manufacturing, a label is far more than a simple supply item,” said Robin Kalsbeek, General Manager of GMP Labeling. “It is a critical element of traceability and compliance.”

Strategic advantages for life sciences

For pharmaceutical and medical device manufacturers, the company’s domestic production model supports specific operational requirements:

Supply Chain Reliability: Stock quality control labels remain available for rapid dispatch to prevent production bottlenecks.Material Continuity: Revision-controlled development and lot segregation practices ensure material consistency, mitigating risk for long-term projects.Regulatory Qualification: The ISO 9001-certified quality management system is open for customer review, facilitating the documentation required for rigorous supplier evaluation programs.Environmental Performance: Specialized engineering enables label durability in demanding conditions, including cryogenic storage, autoclave cycles, and xylene exposure.

GMP Labeling has maintained its manufacturing footprint in the United States since its founding in 1987. The organization provides a stable alternative to international suppliers susceptible to logistics volatility.

This domestic focus ensures that biotech and medical device firms can maintain continuous compliance with safety standards through dedicated account management and technical expertise. The company’s catalog further extends to facility signs, barcode printers, and custom identification solutions designed for cleanroom-compatible applications.

GMP Labeling is a trusted provider of compliance-focused label solutions for medical device, pharmaceutical, biotechnology, and other regulated manufacturing environments. GMP Labeling partners with leading technology and material suppliers to deliver durable, traceable, and customizable labeling systems that support quality, safety, and regulatory requirements. The company’s solutions include quality control labels, custom labels, asset tags, calibration and safety labels, thermal printers, ribbons, and software integration services.

View original content to download multimedia:https://www.prnewswire.com/news-releases/gmp-labeling-celebrates-40-years-of-us-manufacturing-for-regulated-industries-302896698.html

SOURCE GMP Labeling Inc.

Continue Reading

Technology

Midea and Electrolux Group Officially Begin New Chapter in North America as All Three Joint Ventures Go Live

Published

on

By

By combining their complementary strengths, the two companies are creating a more localized and competitive platform to develop innovative products, enhance operational efficiency and support long-term sustainable growth.

CHARLOTTE, N.C., Oct. 2, 2026 /PRNewswire/ — Midea Group and Electrolux Group are advancing their long-term strategic partnership in North America as all three joint ventures are now live. This milestone brings together two global industry leaders with a shared ambition: to strengthen product competitiveness, accelerate innovation and deliver even greater value to consumers and customers.

The partnership was announced on April 23, 2026, building on more than 20 years of collaboration. It brings together the companies’ capabilities in manufacturing, product development, innovation, supply chain and commercial strategies to deliver stronger value to customers and consumers in North America.

“As all three joint ventures go live, the partnership marks a concrete step forward in the companies’ long-term strategy in North America. By bringing our strengths together and working more closely across product development, operations and go-to-market, we can convert years of collaboration into new opportunities to innovate, improve efficiency and better serve consumers and customers,” said Louis Zhao, Vice President of Midea Group & President of Smart Home Business Group.

“This partnership marks a major milestone in the execution of Electrolux Group’s strategy and puts us in a position to accelerate profitable growth. It enables us to continue to invest in sustainable, consumer-centric innovations to serve our customers and consumers with even stronger product offerings in North America,” said Yannick Fierling, President & CEO of Electrolux Group.

Looking ahead, Midea Group and Electrolux Group will continue strengthening local manufacturing and supply capabilities to meet evolving consumer needs. Together, the companies plan to achieve annual North American production of Food Preservation and Fabric Care products that is roughly double current capacity, while also expanding into new product categories.

About Midea Group

Midea is a global technology group covering seven business segments, including smart home, industrial technology, building technologies, robotics and automation, energy, healthcare, as well as smart logistics.  Founded in 1968, Midea serves over 500 million users annually and operates more than 400 subsidiaries, 41 R&D centers and 68 major production bases across more than 200 countries and regions. The group has invested over USD 10.4 billion in R&D over the past five years.

About Electrolux Group

Electrolux Group is a leading global appliance company that has been shaping living for the better for more than 100 years. Through leading brands including Electrolux, AEG and Frigidaire, the group delivers solutions across taste, care and well-being to consumers in around 120 markets, with sustainability at the heart of its products and operations. In 2025, Electrolux Group recorded sales of 131 billion Swedish kronor and employed approximately 39,000 people worldwide.

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/midea-and-electrolux-group-officially-begin-new-chapter-in-north-america-as-all-three-joint-ventures-go-live-302896705.html

SOURCE Midea Group Co., Ltd

Continue Reading

Trending